# Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

> **NCT05567588** · PHASE2 · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 66 (estimated)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Drug: Pembrolizumab

## Key facts

- **NCT ID:** NCT05567588
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-31
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567588, "Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05567588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*